Surrozen Presents Data Demonstrating the Promise of Antibody-Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at the Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting
May 09, 2024 08:30 ET
|
Surrozen, Inc.
Surrozen Presents Data Demonstrating the Promise of Antibody Based Wnt Mimetics in Treating Cornea Endothelial Dystrophies and Dry Eye Disease at ARVO 2024
Surrozen Provides First Quarter 2024 Financial Results and Business Update
May 08, 2024 16:05 ET
|
Surrozen, Inc.
Surrozen Provides First Quarter 2024 Financial Results and Business Update
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
April 03, 2024 08:40 ET
|
Surrozen, Inc.
Surrozen Publishes Study in 'Respiratory Research' Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary Fibrosis
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
April 01, 2024 08:30 ET
|
Surrozen, Inc.
Surrozen Announces Safety, Pharmacodynamic and Liver Function Data for SZN-043
Surrozen Announces up to $192.5 Million Private Placement of Securities Priced At-the-Market Under Nasdaq Rules
April 01, 2024 08:30 ET
|
Surrozen, Inc.
Surrozen Announces up to $192.5 Million Private Placement of Securities
Priced At-the-Market Under Nasdaq Rules
Surrozen Provides Corporate Update on Clinical Programs
January 18, 2024 08:30 ET
|
Surrozen, Inc.
Announces strategic prioritization of clinical programs to focus on development of SZN-043 for Alcohol-Associated Hepatitis SZN-043- Completed enrollment for the Phase 1a clinical trial in chronic...
Surrozen Provides Third Quarter 2023 Financial Results
November 08, 2023 16:05 ET
|
Surrozen, Inc.
Expect to announce data from SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers in Q1 2024 Expect to announce data from SZN-1326 Phase 1a clinical...
Surrozen Provides Second Quarter 2023 Financial Results
August 09, 2023 16:05 ET
|
Surrozen, Inc.
SZN-043 Phase 1a clinical trial in patients with chronic liver disease and in healthy volunteers continues to enroll with safety data expected by the end of 2023 SZN-1326 Phase 1a clinical trial in...
Surrozen Publishes Study in Nature Communications Demonstrating the Promise of a Fzd4 Wnt Antibody in Treating Ischemic Stroke
June 05, 2023 08:30 ET
|
Surrozen, Inc.
In a preclinical model of ischemic stroke, systemic delivery of a selective Fzd4 Wnt antibody strongly reduced blood-brain-barrier leakage, death of surrounding brain tissue, tissue swelling, while...
Surrozen Provides First Quarter 2023 Financial Results and Corporate and Pipeline Updates
May 10, 2023 16:05 ET
|
Surrozen, Inc.
Enrollment ongoing in SZN-043 Phase 1a clinical trial in people with chronic liver disease and in healthy volunteers with safety data expected by the end of 2023 Enrollment ongoing in SZN-1326 Phase...